PSMA 生物学、PSMA 成像和内放射治疗策略不断演变的故事述评。
A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.
机构信息
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Imaging Institute and Cancer Biology Department, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
出版信息
J Nucl Med. 2018 Jul;59(7):1007-1013. doi: 10.2967/jnumed.117.203877. Epub 2018 Apr 19.
Abstract
In this review, we cover the evolution of knowledge on the biology of prostate-specific membrane antigen (PSMA) and its translation to therapy. The usual key to discovery is a realistic model for experimentation and for testing a hypothesis. A realistic model is especially needed in the case of the human prostate, which differs significantly from the prostate of species often used as research models. We will emphasize the genetic characterization of PSMA, the nature of the PSMA protein, and its role as a carboxypeptidase, with differing important substrates and products in different tissues. We give special prominence to the importance of PSMA as a target for imaging and therapy in prostate cancer and its underdeveloped role for imaging and targeting the neovasculature of tumors other than prostate cancer. Lastly, we bring attention to its importance in other nonprostatic tissues.
摘要
在这篇综述中，我们介绍了前列腺特异性膜抗原（PSMA）的生物学知识的发展及其向治疗学的转化。通常，发现的关键是一个用于实验和检验假设的现实模型。在人类前列腺的情况下，尤其需要这样一个现实模型，因为它与通常用作研究模型的物种的前列腺有很大的不同。我们将强调 PSMA 的遗传特征、PSMA 蛋白的性质及其作为羧肽酶的作用，不同组织中具有不同的重要底物和产物。我们特别强调 PSMA 作为前列腺癌成像和治疗靶点的重要性，以及其在成像和靶向除前列腺癌以外的肿瘤新生血管方面的未充分发挥的作用。最后，我们提请注意它在其他非前列腺组织中的重要性。
相似文献
1
A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.PSMA 生物学、PSMA 成像和内放射治疗策略不断演变的故事述评。
J Nucl Med. 2018 Jul;59(7):1007-1013. doi: 10.2967/jnumed.117.203877. Epub 2018 Apr 19.
2
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.靶向前列腺特异性膜抗原（PSMA）的放射性标记酶抑制剂和结合剂：用于前列腺癌成像和治疗的有效诊疗工具。
Nucl Med Biol. 2016 Nov;43(11):692-720. doi: 10.1016/j.nucmedbio.2016.08.006. Epub 2016 Aug 11.
3
Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.基于谷氨酸脲的前列腺特异性膜抗原（PSMA）靶向放射性治疗药物的内化设计
Theranostics. 2016 Apr 28;6(8):1085-95. doi: 10.7150/thno.13448. eCollection 2016.
4
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.68Ga- 和 177Lu-标记的 PSMA I&T：PSMA 靶向治疗概念的优化及首例概念验证人体研究。
J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18.
5
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.前列腺特异性膜抗原（PSMA）靶向 PET 成像在前列腺癌中的应用：重要陷阱的最新研究进展。
Semin Nucl Med. 2019 Jul;49(4):255-270. doi: 10.1053/j.semnuclmed.2019.02.006. Epub 2019 Mar 4.
6
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.用于前列腺癌诊断和治疗的PSMA配体的兴起
J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S. doi: 10.2967/jnumed.115.170720.
7
Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.核医学中前列腺特异性膜抗原靶向的现状：含前列腺特异性膜抗原配体的螯合剂在前列腺癌诊断与治疗中的临床转化
Semin Nucl Med. 2016 Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004.
8
Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.前列腺特异性膜抗原 PET：在前列腺癌中的临床应用、正常表现、要点和陷阱。
Radiographics. 2018 Jan-Feb;38(1):200-217. doi: 10.1148/rg.2018170108.
9
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.肿瘤靶点前列腺特异性膜抗原（PSMA）及其在前列腺癌中的调控
J Cell Biochem. 2004 Feb 15;91(3):528-39. doi: 10.1002/jcb.10661.
10
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.一种定制的、带有优化连接基团的DOTA偶联PSMA抑制剂用于前列腺癌成像和内放射治疗的临床前评估
J Nucl Med. 2015 Jun;56(6):914-20. doi: 10.2967/jnumed.114.147413. Epub 2015 Apr 16.
引用本文的文献
1
Radionuclides Landscape in Prostate Cancer Theranostics.前列腺癌诊疗中的放射性核素概况
Int J Mol Sci. 2025 Jul 14;26(14):6751. doi: 10.3390/ijms26146751.
2
Predicting side-specific extraprostatic extension in prostate cancer using an 18F-DCFPyL PSMA-PET/CT-based nomogram.使用基于18F-DCFPyL PSMA-PET/CT的列线图预测前列腺癌侧别特异性前列腺外扩展
Prostate Cancer Prostatic Dis. 2025 Jul 23. doi: 10.1038/s41391-025-01001-7.
3
Robot-Assisted Radical Prostatectomy: Concordance and Correlation Between Preoperative Positron Emission Tomography-Computed Tomography With Prostate-Specific Membrane Antigen (PET-CT PSMA) and Final Histopathological Report.机器人辅助根治性前列腺切除术：术前前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描（PET-CT PSMA）与最终组织病理学报告之间的一致性和相关性
Cureus. 2025 Apr 10;17(4):e82019. doi: 10.7759/cureus.82019. eCollection 2025 Apr.
4
Neovascular prostate specific membrane antigen (PSMA) expression in bone and soft tissue sarcoma: a systematic analysis.骨与软组织肉瘤中新生血管前列腺特异性膜抗原（PSMA）的表达：一项系统分析。
Virchows Arch. 2025 Apr 9. doi: 10.1007/s00428-025-04086-6.
5
Prostate-specific membrane antigen-targeting radiopharmaceuticals: a new frontier in hepatic malignancies.前列腺特异性膜抗原靶向放射性药物：肝脏恶性肿瘤治疗的新前沿
Front Oncol. 2025 Mar 7;15:1547459. doi: 10.3389/fonc.2025.1547459. eCollection 2025.
6
Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.低分子量前列腺特异性膜抗原放射性同位素标记作为转移性去势抵抗性前列腺癌治疗诊断剂的未来前景
Molecules. 2024 Dec 23;29(24):6062. doi: 10.3390/molecules29246062.
7
CXCR2 expression is associated with prostate-specific membrane antigen expression in hepatocellular carcinoma: reappraisal of tumor microenvironment and angiogenesis.CXCR2表达与肝细胞癌中前列腺特异性膜抗原表达相关：肿瘤微环境与血管生成的重新评估
Clin Transl Oncol. 2025 Jun;27(6):2544-2556. doi: 10.1007/s12094-024-03789-7. Epub 2024 Dec 5.
8
Standardized template for clinical reporting of PSMA PET/CT scans.PSMA PET/CT 扫描临床报告的标准化模板。
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):335-341. doi: 10.1007/s00259-024-06857-w. Epub 2024 Aug 15.
9
Parathyroid Adenoma Detected in Ga-PSMA PET/CT but Not in the Dedicated Imaging Modalities.甲状旁腺腺瘤在镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描（Ga-PSMA PET/CT）中被检测到，但在专门的成像模态中未被检测到。
Diagnostics (Basel). 2024 Aug 5;14(15):1690. doi: 10.3390/diagnostics14151690.
10
Diagnostic efficacy of [Tc]Tc-PSMA SPECT/CT for prostate cancer: a meta-analysis.[Tc]Tc-PSMA SPECT/CT 对前列腺癌的诊断效能：一项荟萃分析。
BMC Cancer. 2024 Aug 8;24(1):982. doi: 10.1186/s12885-024-12734-4.
本文引用的文献
1
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms.使用 PSMA 靶向放射性示踪剂对非前列腺癌进行成像：基本原理、当前领域状况和行动呼吁。
J Nucl Med. 2018 Jun;59(6):871-877. doi: 10.2967/jnumed.117.203570. Epub 2018 Mar 15.
2
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.针对转移性去势抵抗性前列腺癌的靶向 α 治疗：Ac-PSMA-617 的游泳者图分析提示了肿瘤控制持续时间的疗效。
J Nucl Med. 2018 May;59(5):795-802. doi: 10.2967/jnumed.117.203539. Epub 2018 Jan 11.
3
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.维生素 B9 的前列腺特异性膜抗原裂解通过代谢型谷氨酸受体刺激致癌信号。
J Exp Med. 2018 Jan 2;215(1):159-175. doi: 10.1084/jem.20171052. Epub 2017 Nov 15.
4
Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.小鼠谷氨酸羧肽酶II（GCPII）具有与人类GCPII相似的酶活性和抑制特性，但组织分布不同。
FEBS Open Bio. 2017 Aug 29;7(9):1362-1378. doi: 10.1002/2211-5463.12276. eCollection 2017 Sep.
5
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.用于成像和治疗的前列腺特异性膜抗原配体
J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S. doi: 10.2967/jnumed.116.186767.
6
Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.基于谷氨酸-脲基的前列腺特异性膜抗原抑制剂：新型低分子量治疗诊断放射性示踪剂研发过程中的经验教训。
J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S. doi: 10.2967/jnumed.116.186775.
7
Lu-PSMA Radioligand Therapy for Prostate Cancer.镥-PSMA 放射性配体疗法治疗前列腺癌。
J Nucl Med. 2017 Aug;58(8):1196-1200. doi: 10.2967/jnumed.117.191023. Epub 2017 Jun 29.
8
Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?推动PSMA靶向诊疗技术走向临床：常识能否占上风？
J Nucl Med. 2017 Aug;58(8):1186-1187. doi: 10.2967/jnumed.117.193516. Epub 2017 May 4.
9
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.
10
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo".前列腺特异性膜抗原（PSMA）组装一种大分子复合物，该复合物在体外调节前列腺癌细胞的生长和存活，并与体内进展相关。
Oncotarget. 2016 Nov 8;7(45):74189-74202. doi: 10.18632/oncotarget.12404.
Zotero 插件